180 related articles for article (PubMed ID: 37569750)
1. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.
Huang Y; Fan Y; Zhao Z; Zhang X; Tucker K; Staley A; Suo H; Sun W; Shen X; Deng B; Pierce SR; West L; Yin Y; Emanuele MJ; Zhou C; Bae-Jump V
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569750
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer.
Yang W; Cho H; Shin HY; Chung JY; Kang ES; Lee EJ; Kim JH
Oncotarget; 2016 Aug; 7(31):49481-49497. PubMed ID: 27385216
[TBL] [Abstract][Full Text] [Related]
3. The aberrant upstream pathway regulations of CDK1 protein were implicated in the proliferation and apoptosis of ovarian cancer cells.
Zhang R; Shi H; Ren F; Zhang M; Ji P; Wang W; Liu C
J Ovarian Res; 2017 Sep; 10(1):60. PubMed ID: 28899430
[TBL] [Abstract][Full Text] [Related]
4. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
Suri A; Sheng X; Schuler KM; Zhong Y; Han X; Jones HM; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Jun; 7(26):39582-39594. PubMed ID: 27074576
[TBL] [Abstract][Full Text] [Related]
5. Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.
Guo H; Zhong Y; Jackson AL; Clark LH; Kilgore J; Zhang L; Han J; Sheng X; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Apr; 7(15):20338-56. PubMed ID: 26959121
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division.
Cedeno-Rosario L; Honda D; Sunderland AM; Lewandowski MD; Taylor WR; Chadee DN
J Biol Chem; 2022 Aug; 298(8):102263. PubMed ID: 35843311
[TBL] [Abstract][Full Text] [Related]
7. DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression.
Wang LL; Sun KX; Wu DD; Xiu YL; Chen X; Chen S; Zong ZH; Sang XB; Liu Y; Zhao Y
J Cell Mol Med; 2017 Nov; 21(11):3055-3065. PubMed ID: 28598010
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression.
Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
Cancer Lett; 2015 Jun; 362(1):122-30. PubMed ID: 25819031
[TBL] [Abstract][Full Text] [Related]
9. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
Li J; Zhi X; Shen X; Chen C; Yuan L; Dong X; Zhu C; Yao L; Chen M
Biochem Biophys Res Commun; 2020 Mar; 523(2):434-440. PubMed ID: 31875843
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
Shi HR; Zhang RT
Ai Zheng; 2009 Aug; 28(8):882-5. PubMed ID: 19664338
[TBL] [Abstract][Full Text] [Related]
11. Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells.
Leng Y; Zhao C; Yan G; Xu S; Yang Y; Gong T; Li X; Li C
J Ovarian Res; 2021 Nov; 14(1):162. PubMed ID: 34789301
[TBL] [Abstract][Full Text] [Related]
12. CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner.
Prevo R; Pirovano G; Puliyadi R; Herbert KJ; Rodriguez-Berriguete G; O'Docherty A; Greaves W; McKenna WG; Higgins GS
Cell Cycle; 2018; 17(12):1513-1523. PubMed ID: 30045664
[TBL] [Abstract][Full Text] [Related]
13. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
14. TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination.
Sisinni L; Maddalena F; Condelli V; Pannone G; Simeon V; Li Bergolis V; Lopes E; Piscazzi A; Matassa DS; Mazzoccoli C; Nozza F; Lettini G; Amoroso MR; Bufo P; Esposito F; Landriscina M
J Pathol; 2017 Sep; 243(1):123-134. PubMed ID: 28678347
[TBL] [Abstract][Full Text] [Related]
15. CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity.
Sunada S; Saito H; Zhang D; Xu Z; Miki Y
Biochem Biophys Res Commun; 2021 Apr; 550():56-61. PubMed ID: 33684621
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.
Kojima K; Shimanuki M; Shikami M; Andreeff M; Nakakuma H
Cancer Sci; 2009 Jun; 100(6):1128-36. PubMed ID: 19385969
[TBL] [Abstract][Full Text] [Related]
17. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.
Xi Q; Huang M; Wang Y; Zhong J; Liu R; Xu G; Jiang L; Wang J; Fang Z; Yang S
Tumour Biol; 2015 Jul; 36(7):4939-48. PubMed ID: 25910705
[TBL] [Abstract][Full Text] [Related]
18. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
[TBL] [Abstract][Full Text] [Related]
19. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells.
Xiao D; Johnson CS; Trump DL; Singh SV
Mol Cancer Ther; 2004 May; 3(5):567-75. PubMed ID: 15141014
[TBL] [Abstract][Full Text] [Related]
20. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
